AKERO THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO

Core Viewpoint - A securities class action lawsuit has been filed against Akero Therapeutics, Inc. for failing to disclose material information during the Class Period, which has led to significant stock price declines following the revelation of study results [1][2][4]. Group 1: Lawsuit Details - Investors have until June 25, 2024, to file lead plaintiff applications in the lawsuit against Akero Therapeutics [1]. - The lawsuit is pending in the United States District Court for the Northern District of California [1]. - The case is identified as Klobus v. Akero Therapeutics, Inc., No. 24-cv-02534 [4]. Group 2: Allegations Against Akero - Akero and its executives are accused of not disclosing that approximately 20% of patients in the SYMMETRY study had cryptogenic cirrhosis, which misrepresented the study's results [3]. - The company allegedly introduced confounding factors into the SYMMETRY study's design, which could materially influence the study's outcomes [3]. - It is claimed that the SYMMETRY study did not align with FDA guidance for testing drugs in treating NASH cirrhotics, leading to misrepresentation of the trial's nature and potential success [3]. Group 3: Market Reaction - On October 10, 2023, Akero disclosed the SYMMETRY study's 36-week results, resulting in a stock price drop of $30.39 per share, followed by an additional decline of $3.11 per share on the next day, totaling a nearly 70% decrease from the previous closing price of $48.54 [4].